- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- Interventions
- PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis
- Biological · Drug · Device + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 3,607
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
- Interventions
- Combination of varlilumab and nivolumab
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- Multiple Myeloma
- Interventions
- MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
- Biological
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
- Conditions
- Solid Tumor
- Interventions
- Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
- Conditions
- Cancer of Rectum
- Interventions
- combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Lakewood, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 2 more
- Conditions
- HIV Infections
- Interventions
- Ritonavir, Nelfinavir mesylate, Saquinavir, Nevirapine, Lamivudine, Stavudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years to 22 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
- Interventions
- denintuzumab mafodotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- ALX-0061, Placebo, Methotrexate
- Biological · Other · Drug
- Lead sponsor
- Ablynx, a Sanofi company
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Hemet, California • La Palma, California + 18 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug 1: LY3023414; Drug 2: Prexasertib
- Combination Product
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Colon Cancer
- Interventions
- Perifosine, Capecitabine, Perifosine Placebo
- Drug · Other
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Beverly Hills, California • Deer Park, California + 45 more
- Conditions
- Bone Fracture, Fresh Fracture
- Interventions
- Sustained Acoustic Device with 2.5% Diclofenac Patch, 2.5% Diclofenac Patches
- Device · Drug
- Lead sponsor
- ZetrOZ, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Trumbull, Connecticut • Lansdowne, Virginia
- Conditions
- Opioid Addiction
- Interventions
- FMRI, Suboxone
- Other · Drug
- Lead sponsor
- Butler Hospital
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Osteomyelitis of Jaw
- Interventions
- Amoxicillin-clavulanate 875mg/125mg q12hrs, oral clindamycin 300mg q6hrs, Levofloxacin 750mg QID
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Mesothelioma, Peritoneal Mesothelioma
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Glioblastoma
- Interventions
- Re-irradiation (RT), Bevacizumab, Nivolumab, Re-resection
- Radiation · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 11
- States / cities
- Hartford, Connecticut • Indianapolis, Indiana • Basking Ridge, New Jersey + 8 more
- Conditions
- Multiple Myeloma
- Interventions
- CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- HER2-positive Metastatic Breast Cancer
- Interventions
- Alpelisib, Tucatinib, Fulvestrant
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Tivozanib, Nivolumab
- Drug
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 36
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 31 more
- Conditions
- Heart Failure
- Interventions
- Sacubitril/valsartan, ACEI or ARB and no sacubitril/valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,614,719 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
- Interventions
- Niraparib, Trastuzumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Rochester, Minnesota + 4 more
- Conditions
- HIV Infections
- Interventions
- Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more
- Conditions
- Hepatitis C
- Interventions
- Sofosbuvir/Ledipasvir x 12 weeks, Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more